ILXQuant Obesity and Metabolic Health Basket Index
Fixed-basket index of 10 companies at the centre of the GLP-1 obesity drug revolution -- originators (Novo Nordisk, Eli Lilly), next-generation oral challengers (Viking Therapeutics, Structure Therapeutics), competing platforms (Amgen), telehealth distribution (Hims and Hers), continuous glucose monitoring (DexCom), rare obesity (Rhythm Pharmaceuticals), and liver/metabolic disease (Madrigal, Tern). Rebalances quarterly to equal weight. GLP-1 drugs are on track to become the largest-revenue drug category in history with benefits extending beyond weight loss.
- Index identifier
- ILXGLP
- Category
- Basket
- Universe
- Fixed basket -- 10 obesity and metabolic health companies (equal weight)
- Currency
- USD
- Inception
- 2023-03-06
- Rebalancing
- Quarterly (first Monday of March, June, September, December)
- Index fee
- 0.60% p.a.
- Reference benchmark
- Health Care SPDR (XLV)
Performance and risk
All figures below are measured over a trailing window of up to 1,260 trading days (approximately five years), not since index inception.
| Annualised return | +54.98% |
|---|---|
| Sharpe ratio | 1.54 |
| Calmar ratio | 1.64 |
| Volatility | 35.77% |
| Maximum drawdown | -33.44% |
| Return, 1 month | — |
| Return, 3 months | — |
| Return, 1 year | — |
| Return, year to date | +2.49% |
Full performance history, drawdown analysis, rolling risk metrics and portfolio breakdowns for this index are available in the ILX Quant platform.